The kinetoplastid chemotherapy revisited: Current drugs, recent advances and future perspectives

Current Medicinal Chemistry

Volumn 17, Issue 33, 2010, Pages 4027-4051

  Castillo, E ^a   Dea Ayuela, M A ^a,b   Bolas Fernandez F ^b   Rangel, M ^a   Gonzalez Rosende M E ^a  

^a UNIVERSIDAD CEU CARDENAL HERRERA   (Spain)

^b UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

African sleeping sickness; Anti leishmanial chemotherapy; Chagas disease; Drugs formulations; Leishmaniasis; Trypanocidal chemotherapy

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; BENZNIDAZOLE; EFLORNITHINE; MEGLUMINE ANTIMONATE; MELARSOPROL; MILTEFOSINE; NIFURTIMOX; PAFURAMIDINE; PAROMOMYCIN; PENTAMIDINE; POSACONAZOLE; PYRROLE; STIBOGLUCONATE SODIUM; SURAMIN;

AFRICAN TRYPANOSOMIASIS; CHAGAS DISEASE; KINETOPLASTIDA; LEISHMANIASIS; NONHUMAN; REVIEW; SKIN LEISHMANIASIS; VISCERAL LEISHMANIASIS;

ANIMALS; ANTIPROTOZOAL AGENTS; CHAGAS DISEASE; CLINICAL TRIALS AS TOPIC; DRUG DESIGN; DRUG DISCOVERY; DRUG THERAPY, COMBINATION; HUMANS; LEISHMANIA; LEISHMANIASIS; TRYPANOCIDAL AGENTS; TRYPANOSOMA BRUCEI BRUCEI; TRYPANOSOMA CRUZI; TRYPANOSOMIASIS, AFRICAN;

EID: 79251504276     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793205345     Document Type: Review

References (193)

1. Stuart, K.; Brun, R.; Croft, S.L.; Fairlamb, A.; Gürtler, R.E.; McKerrow, J.; Reed, S.; Tarleton, R. Kinetoplastids: Related protozoan pathogens, different diseases. J. Clin. Invest., 2008, 118, 1301-1310.
2. Molyneux, D. Control of Human Parasitic Diseases, Elsevier Books: Oxford, 2007.
3. Minodier, P.; Parola, P. Cutaneous leishmaniasis treatment. Travel Med. Infect. Dis., 2007, 5, 150-158.
4. Amato, V.S.; Tuon, F.F.; Bacha, H.A.; Neto, V.A.; Nicodemo, A.C. Mucosal leishmaniasis. Current scenario and prospects for treatment. Acta Trop., 2008, 105, 1-9.
5. Sundar, S.; Chatterje, M. Visceral leishmaniasis - current therapeutic modalities. Indian J. Med. Res., 2006, 123, 345-352.
6. Zijlstra, E.E.; Musa, A.M.; Khalil, E.A.G.; El Hassan, I.M.; El- Hassan, A.M. Post -kala-azar dermal leishmaniasis. Lancet infect. Dis., 2003, 3, 87-98.
7. Croft, S.L. Kinetoplastida: New therapeutic strategies. Parasite, 2008, 15, 522-527.
8. Mishra, J.; Saxena, A.; Singh, S. Chemotherapy of leishmaniasis: Past, present and future. Curr. Med. Chem., 2007, 14, 1153-1169.
9. Croft, S.L.; Seifert, K.; Yardley, V. Current scenario of drug development for leishmaniasis. Indian J. Med. Res., 2006, 123, 399-410.
10. Croft, S.L.; Barret, M.P.; Urbina, J.A. Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol., 2005, 21, 508-512.
11. Davis, A.J.; Kedzierski, L. Recent advances in antileishmanial drug development. Curr. Opin. Investig. Drugs, 2005, 6, 163-169.
12. Croft, S.L.; Sundar, S.; Fairlamb, A.H. Drug resistance in leishmaniasis. Clin. Microbiol. Rev., 2006, 19, 111-126.
13. Ouellette, M.; Drummelsmith, J.; Papadopoulou, B. Leishmaniasis: Drugs in the clinic, resistance and new developments. Drug Resist. Updat., 2004, 7, 257-266.
14. Moncayo, A.; Ortiz Yanine, M.I. An update on Chagas disease (human American trypanosomiasis). Ann. Trop. Med. Parasitol., 2006, 100, 663-677.
15. Paulino, M.; Iribarne, F.; Dubin, M.; Aguilera-Morales, S.; Tapia, O.; Stoppani, A. O. M. The chemotherapy of Chagas' disease: An overview. Mini Rev. Med. Chem., 2005, 5, 499-519.
16. Urbina, J.A.; Docampo, R. Specific chemotherapy of Chagas disease: Controversies and advances. Trends Parasitol., 2003, 19, 495-501.
17. Kennedy, P.G.E. Human African trypanosomiasis of the CNS: Current issues and challenges. J. Clin. Invest., 2004, 113, 496-504.
18. Delespaux, V.; de Koning, H.P. Drugs and drug resistance in African trypanosomiasis. Drug Resist. Updat., 2007, 10, 30-50.
19. Hotez, P.J.; Molyneux, D.H.; Fenwick, A.; Kumaresan, J.; Ehrlich Sachs, S.; Sachs, J. D.; Savioli, L. Control of neglected tropical diseases. N. Engl. J. Med., 2007, 357, 1018-1027.
20. Frezard, F.; Martins, P.S.; Barbosa, M.C.; Pimenta, A.M.; Ferreira, W.A.; de Melo, J.E.; Mangrum, J.B.; Demicheli, C. New insights into the chemical structure and composition of the pentavalent antimonial drugs, meglumine antimonate and sodium stibogluconate. J. Inorg. Biochem., 2008, 102, 656-665.
21. Zhou, Y.; Messier, N.; Ouellette, M.; Rosen, B.P.; Mukhopadhyay, R. Leishmania major LmACR2 is a pentavalent antimony reductase that confers sensitivity to the drug pentostam. J. Biol. Chem., 2004, 279, 37445-37451.
22. Berman, J.D.; Gallalee, J.V.; Best, J.M. Sodium stibogluconate (Pentostam) inhibition of glucose catabolism via the glycolytic pathway, and fatty acid beta-oxidation in Leishmania mexicana amastigotes. Biochem. Pharmacol., 1987, 36, 197-201.
23. Wyllie, S.; Fairlamb, A.H. Differential toxicity of antimonial compounds and their effects on glutathione homeostasis in a human leukaemia monocyte cell line. Biochem. Pharmacol., 2006, 71, 257-267.
24. Demicheli, C.; Frezard, F.; Lecouvey, M.; Garnier-Suillerot, A. Antimony(V) complex formation with adenine nucleosides in aqueous solution. Biochim. Biophys. Acta, 2002, 1570, 192-198.
25. Sudhandiran, G.; Shaha, C. Antimonial-induced increase in intracellular Ca2+ through non-selective cation channels in the host and the parasite is responsible for apoptosis of intracellular Leishmania donovani amastigotes. J. Biol. Chem., 2003, 278, 25120-25132.
26. Cruz, I.; Nieto, J.; Moreno, J.; Cañavate, C.; Desjeux, P.; Alvar, J. Leishmania/HIV co-infections in the second decade. Indian J. Med. Res., 2006, 123, 357-388.
27. Ashutosh, Sundar, S.; Goyal, N. Molecular mechanisms of antimony resistance in Leishmania. J. Med. Microbiol., 2007, 56, 143-153.
28. Wyllie, S.; Vickers, T.J.; Fairlamb, A.H. Roles of trypanothione Stransferase and tryparedoxin peroxidase in resistance to antimonials. Antimicrob. Agents Chemother., 2008, 52, 1359-1365.
29. Nok, A.J. Arsenicals (melarsoprol), pentamidine and suramin in the treatment of human African trypanosomiasis. Parasitol. Res., 2003, 90, 71-79.
30. Legros, D.; Ollivier, G.; Gastellu-Etchegorry, M.; Paquet, C.; Burri, C.; Jannin, J Büscher, P. Treatment of human African trypanosomiasis- present situation and needs for research and development. Lancet Infect. Dis., 2002, 2, 437-440.
31. Chollet, C.; Valían, A,E.; Wong, P.; Barret, M.P.; Gilbert I.H. Targeted delivery of compounds to Trypanosoma brucei using the melamine motif. Bioorg. Med. Chem., 2009, 17, 2512-2523.
32. Romero, E.L.; Morilla, M.J. Drug delivery systems against leishmaniasis? Still an open question. Expert Opin. Drug Deliv., 2008, 5, 805-823.
33. Wasan, K.M.; Morton, R.E.; Rosenblum, M.G.; Lopez-Berestein, G. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: Role of lipid transfer protein. J. Pharm. Sci., 1994, 83, 1006-1010.
34. Mbongo, N.; Loiseau, P.M.; Billion, M.A.; Robert-Gero, M. Mechanism of amphotericin B resistance in Leishmania donovani promastigotes. Antimicrob. Agents Chemother., 1998, 42, 352-357. (Pubitemid 28114444)
35. Sundar, S.; Chakravarty. J. Paromomycin in the treatment of leishmaniasis. Expert Opin. Investig. Drugs, 2008, 17, 787-794.
36. Davidson, R.N.; den Boer, M.; Ritmeijer, K. Paromomycin. Trans. R. Soc.Trop. Med. Hyg., 2009, 103, 653-660.
37. Sundar, S.; Jha, T.K.; Thakur, C.P.; Sinha, P.K.; Bhattacharya, S.K. Injectable paromomycin for Visceral leishmaniasis in India. N. Engl. J. Med., 2007, 356, 2571-2581.
38. Maarouf, M.; Lawrence, F.; Brown, S.; Robert-Gero, M. Biochemical alterations in paromomycin-treated Leishmania donovani promastigotes. Parasitol. Res., 1997, 83, 198-202.
39. El-On, J.; Sulitzeanu, A.; Schnur, L. F. Leishmania major: Resistance of promastigotes to paromomycin, and susceptibility of amastigotes to paromomycin-methylbenzethonium chloride ointment. Ann. Trop. Med. Parasitol., 1991, 85, 323-328;
40. Fong, D.; Chan, M.M.; Rodriguez, R.; Gately, L.J.; Berman, J.D.; Grogl, M. Paromomycin resistance in Leishmania tropica: Lack of correlation with mutation in the small subunit ribosomal RNA gene. Am. J. Trop. Med. Hyg., 1994, 51, 758-766; Jhingran, A.; Bhavna, C.; Saxena, S.; Barret, M. P.; Madhubala, R. Paromomycin: Uptake and resistance in Leishmania donovani. Mol. Biochem. Parasitol., 2009, 164, 111-117.
41. Docampo, R.; Moreno, S. N. Current chemotherapy of human African trypanosomiasis. Parasitol. Res., 2003, 90, S10-13.
42. Andersen, E.M.; Cruz-Saldarriaga, M.; Llanos-Cuentas, A.; Luz- Cjuno, M.; Echevarria, J.; Miranda-Verastegui, C.; Colina, O.; Berman, J.D. Comparison of meglumine antimoniate and pentamidine for peruvian cutaneous leishmaniasis. Am. J. Trop. Med. Hyg., 2005, 72, 133-137.
43. Antoniou, T.; Gough, K.A. Early-onset pentamidine-associated second-degree heart block and sinus bradycardia: Case report and review of the literature. Pharmacotherapy, 2005, 25, 899-903.
44. Assan, R.; Perronne, C.; Assan, D.; Chotard, L.; Mayaud, C.; Matheron, S.; Zucman, D. Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients. Diabetes Care, 1995, 18, 47-55.
45. Bray, P.G.; Barrett, M.P.; Ward, S.A.; de Koning, H.P. Pentamidine uptake and resistance in pathogenic protozoa: Past, present and future. Trends Parasitol., 2003, 19, 232-239.
46. Basselin, M.; Coombs, G.H.; Barrett, M.P. Putrescine and spermidine transport in Leishmania. Mol. Biochem. Parasitol., 2000, 109, 37-46.
47. Wilson, W.D.; Tanious, F.A.; Mathis, A.; Tevis, D.; Hall, J.E.; Boykin, D.W. Antiparasitic compounds that target DNA. Biochimie, 2008, 90, 999-1014.
48. Fox, K.R.; Sansom, C.E.; Stevens, M.F. Footprinting studies on the sequence-selective binding of pentamidine to DNA. FEBS Lett., 1990, 266, 150-154.
49. Jean-Moreno, V.; Rojas, R.; Goyeneche, D.; Coombs, G.H.; Walker, J. Leishmania donovani: Differential activities of classical topoisomerase inhibitors and antileishmanials against parasite and host cells at the level of DNA topoisomerase I and in cytotoxicity assays. Exp. Parasitol., 2006, 112, 21-30.
50. Mehta, A.; Shaha, C. Apoptotic death in Leishmania donovani promastigotes in response to respiratory chain inhibition: Complex II inhibition results in increased pentamidine cytotoxicity. J. Biol. Chem., 2004, 279, 11798-11813.
51. Coelho, A.C.; Messier, N.; Ouellette, M.; Cotrim, P. C. Role of the ABC transporter PRP1 (ABCC7) in pentamidine resistance in Leishmania amastigotes. Antimicrob. Agents Chemother., 2007, 51, 3030-3032.
52. Mukherjee, A.; Padmanabhan, P.K.; Sahani, M.H.; Barrett, M.P.; Madhubala, R. Roles for mitochondria in pentamidine susceptibility and resistance in Leishmania donovani. Mol. Biochem. Parasitol., 2006, 145, 1-10.
53. Sturk, L.M.; Brock, J.L.; Bagnell, C.R.; Hall, J.E.; Tidwell, R.R. Distribution and quantitation of the anti-trypanosomal diamidine 2,5-bis(4-amidinophenyl)furan (DB75) and its N-methoxy prodrug DB289 in murine brain tissue. Acta Trop., 2004, 91, 131-143.
54. Soeiro, M.N.C.; De Souza, E.M.; Stephens, C.E.; Boykin, D.W. Aromatic diamidines as antiparasitic agents. Expert Opin. Investig. Drugs, 2005, 14, 957-972.
55. Lanteri, C.A.; Tidwell, R.R.; Meshnick, S.R. The mitochondrion is a site of trypanocidal action of the aromatic diamidine DB75 in bloodstream forms of Trypanosoma brucei. Antimicrob. Agents Chemother., 2008, 52, 875-882.
56. Hutchinson, M.P.; Watson, H.J.C. Berenil in the treatment of Trypanosoma gambiense infection in man. Trans. R. Soc. Trop. Med. Hyg., 1962, 56, 227-230.
57. Gomes-Cardoso, l.; Echevarria, A.; Aguiar-Alves, F.; Jansen, A. M.; Leon, L.L. Amidine derivatives are highly effective against Trypanosoma evansi trypomastigotes. Microbios, 1999,100, 181-187.
58. Croft, S.L.; Engel, J. Miltefosine-discovery of the antileishmanial activity of phospholipid derivatives. Trans. R. Soc. Trop. Med. Hyg., 2006, 100, S4-8.
59. Berman, J. Treatment of leishmaniasis with miltefosine: 2008 status. Expert Opin. Drug Metab. Toxicol., 2008, 4, 1209-1216.
60. Sindermann, H.; Engel, J. Development of miltefosine as an oral treatment for leishmaniasis. Trans. R. Soc. Trop. Med. Hyg., 2006, 100, S17-20.
61. Soto, J.; Arana, B.A.; Toledo, J.; Rizzo, N.; Vega, J.C.; Diaz, A.; Luz, M.; Gutierrez, P.; Arboleda, M.; Berman, J.D.; Junge, K.; Engel, J.; Sindermann, H. Miltefosine for new world cutaneous leishmaniasis. Clin. Infect. Dis., 2004, 38, 1266-1272.
62. Lux, H.; Heise, N.; Klenner, T.; Hart, D.; Opperdoes, F.R. Etherlipid (alkyl-phospholipid) metabolism and the mechanism of action of ether-lipid analogues in Leishmania. Mol. Biochem. Parasitol., 2000, 111, 1-14.
63. Paris, C.; Loiseau, P.M.; Bories, C.; Breard, J. Miltefosine induces apoptosis-like death in Leishmania donovani promastigotes. Antimicrob. Agents Chemother., 2004, 48, 852-859.
64. Verma, N.K.; Singh, G.; Dey, C.S. Miltefosine induces apoptosis in arseniteresistant Leishmania donovani promastigotes through mitochondrial dysfunction. Exp. Parasitol., 2007, 116, 1-13.
65. Castanys-Muñoz, E.; Alder-Baerens, N.; Pomorski, T.; Gamarro, F.; Castanys, S. A novel ATP-binding cassette transporter from Leishmania is involved in transport of phosphatidylcholine analogues and resistance to alkyl-phospholipids. Mol. Microbiol., 2007, 64, 1141-1153.
66. Pérez-Victoria, F.J.; Sanchez-Cañete, M.P.; Seifert, K.; Croft, S.L.; Sundar, S.; Castanys, S.; Gamarro, F. Mechanisms of experimental resistance of Leishmania to miltefosine: Implications for clinical use. Drug Resist. Updat., 2006, 9, 26-39.
67. Choudhury, K.; Zander, D.; Kube, M., Reinhardt, R.; Clos, J. Identification of a Leishmania infantum gene mediating resistance to miltefosine and SbIII. Int. J. Parasitol., 2008, 38, 1411-1423.
68. Cabrera-Serra, M.G.; Valladares, B.; Piñero J.E. In vivo activity of perifosine against Leishmania amazonensis. Acta Trop., 2008, 108, 20-25.
69. Croft S.L; Snowdon D; Yardley V. The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei. J. Antimicrob. chemother. 1996, 38, 1041-1047.
70. Avlonitis, N.; Lekka, E.; Detsi, A.; Koufaki, M.; Calogeropoulou, T.; Skoulica, E.; Siapi, E.; Kyrikou, I.; Mavromoustakos, T.; Tsotinis, A.; Golic Grdadolnik, S.; Makriyannis, A. Antileishmanial ring-substituted ether phospholipids. J. Med. Chem., 2003, 46, 755-767.
71. Barrett, M.P.; Burchmore, R.J.S.; Stich, A.; Lazzari, J.O.; Frasch, A.C.; Cazzulo, J. J.; Krishna, S. The trypanosomiases. Lancet, 2003, 362, 1469-1480.
72. Van Nieuwenhove, S. In Progress in Human African Trypanosomiasis, Sleeping Sickness, Dumas, M., Bouteille, B., Buguet, A. Eds.; Springer-Verlag: Paris, 1999; pp. 253-280.
73. Docampo, R.; Moreno, S. N. J. Free radical metabolism of antiparasitic agents. Fed. Proc., 1986, 45, 2471-2476.
74. Maya, J.D.; Rodríguez, A.; Pino, L.; Pabon, A.; Ferreira, J.; Pavani, M.; Repetto, Y.; Morello, A. Effects of buthionine sulfoximine nifurtimox and benznidazole upon trypanothione and metallothionein proteins in Trypanosoma cruzi. Biol. Res., 2004, 37, 61-69.
75. Díaz de Toranzo, E.G.; Castro, J. A.; Franke de Cazzulo, B.M.; Cazzulo, J.J. Interaction of benznidazole reactive metabolites with nuclear and kinetoplastid DNA, proteins and lipids from Trypanosoma cruzi. Experientia, 1988, 44, 880-881.
76. Mester, B.; Elguero, J.; Claramunt, R.M.; Castanys, S.; Mascaró, M.L.; Osuna, A. M.; Vilaplana, J.; Molina, P. Activity against Trypanosoma cruzi of new analogues of nifurtimox. Arch. Pharm., 1987, 320, 115-120;
77. Cerecetto, H.; Mester, B.; Onetto, S.; Seoane, G. Formal potentials of new analogues of nifurtimox: Relationship to activity. FARMACO, 1992, 47, 1207-1213.
78. Sjoerdsma, A.; Schechter, P.J. Eflornithine for African sleeping sickness. Lancet, 1999, 354, 254.
79. Wang, C.C. Molecular mechanisms and therapeutic approaches to the treatment of African trypanosomiasis. Annu. Rev. Pharmacol. Toxicol., 1995, 35, 93-127.
80. Vansterkenburg, E.L.M.; Coppens, I.; Wilting, J.; Bos, O.J.M.; Fischer, M.J.E.; Janssen, L.H.M.; Opperdoes, F.R. The uptake of the trypanocidal drug suramin in combination with low-density lipoproteins by Trypanosoma brucei and its possible mode of action. Acta Trop., 1993, 54, 237-250.
81. Yeates, C. Sitamaquine (GlaxoSmithKline/Walter Reed Army Institute). Curr. Opin. Investig. Drugs, 2002, 3, 1446-1452.
82. Jha, T.K.; Sundar, S.; Thakur, C.P.; Felton, J.M.; Sabin, A.J.; Horton, J. A phase II dose-ranging study of sitamaquine for the treatment of visceral leishmaniasis in India. Am. J. Trop. Med. Hyg., 2005, 73, 1005-1011. (Pubitemid 43038244)
83. Vercesi, A.E.; Rodrigues, C.O.; Catisti, R.; Docampo, R. Presence of a Na(+)/H(+) exchanger in acidocalcisomes of Leishmania donovani and their alkalization by anti-leishmanial drugs. FEBS Lett., 2000, 473, 203-206.
84. López-Martín, C.; Pérez-Victoria, J.M.; Carvalho, L.; Castanys, S.; Gamarro, F. Sitamaquine sensitivity in Leishmania species is not mediated by drug accumulation in acidocalcisomes. Antimicrob. Agents Chemother., 2008, 52, 4030-4036.
85. Buates, S.; Matlashewski, G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: Efficacy and mode of action. J. Infect. Dis., 1999, 179, 1485-1494.
86. Seeberger, J.; Daoud, S.; Pammer, J. Transient effect of topical treatment of cutaneous leishmaniasis with imiquimod. Int. J. Dermatol., 2003, 42, 576-579.
87. Chunge, C.N.; Gachihi, G.; Muigai, R.; Wasunna, K.; Rashid, J.R.; Chulay, J.D.; Anabwani, G.; Oster, C.N.; Bryceson, A.D. Visceral leishmaniasis unresponsive to antimonial drugs III. Successful treatment using a combination of sodium stibogluconate plus allopurinol. Trans. R. Soc. Trop. Med. Hyg., 1985, 79, 715-718.
88. Melaku, Y.; Collin, S.M.; Keus, K.; Gatluak, F.; Ritmeijer, K.; Davidson, R. N. Treatment of kala-azar in southern Sudan using a 17- day regimen of sodium stibogluconate combined with paromomycin: A retrospective comparison with 30-day sodium stibogluconate monotherapy. Am. J. Trop. Med. Hyg., 2007, 77, 89-94.
89. Sadeghian, G.; Nilforoushzadeh, M.A. Effect of combination therapy with systemic glucantime and pentoxifylline in the treatment of cutaneous leishmaniasis. Int. J. Dermatol., 2006, 45, 819-821.
90. Nieves, M.; Díaz, E.; Machuca, C.; Romero, A.; Ponte Sucre, A. Glibenclamide modulates glucantime activity and disposition in Leishmania major. Exp. Parasitol., 2009, 121, 331-337.
91. Serrano-Martín, X.; Payares, G.; Mendoza-León, A. Glibenclamide, a blocker of K+(ATP) channels, shows antileishmanial activity in experimental murine cutaneous leishmaniasis. Antimicrob. Agents Chemother., 2006, 50, 4214-4216.
92. Sundar, S.; Rai, M.; Chakravarty, J.; Agarwal, D.; Agrawal, N.; Vaillant, M.; Olliaro, P.; Murray, H. W. New treatment approach in Indian visceral leishmaniasis: Single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin. Infect. Dis., 2008, 47, 1000-1006.
93. Urbina, J.A.; Lazardi, K.; Aguirre, T.; Piras, M.M.; Piras. R. Antiproliferative synergism of the allylamine SF 86-327 and ketoconazole on epimastigotes and amastigotes of Trypanosoma (Schizotrypanum) cruzi. Antimicrob. Agents Chemother., 1988, 32, 1237-1242.
94. Urbina, J.A.; Lazardi, K.; Marchan, E.; Visbal,G.; Aguirre,T.; Piras, M.M.; Piras, R.; Maldonado, R.A.; Payares,G.; De Souza, W. Mevinolin (lovastatin) potentiates the antiproliferative effects of ketoconazole and terbinafine against Trypanosoma (schizotrypanum) cruzi: In vitro and in vivo studies. Antimicrob. Agents Chemother., 1993, 37, 580-591.
95. Benaim, G.; Sanders, J.M.; Garcia-Marchan, Y.; Colina, C.; Lira, R.; Caldera, A.R.; Payares, G.; Sanoja, C.; Burgos, J.M.; Leon- Rossell, A.; Concepción, J.L.; Schijman, A.G.; Levin, M.; Oldfield, E.; Urbina, J.A. Amiodarone has intrinsic anti-Trypanosoma cruzi activity and acts synergistically with Posaconazole. J. Med. Chem., 2006, 49, 892-899.
96. Santa-Rita, R.M.; Lira, R.; Barbosa, H.S.; Urbina, J.A.; de Castro, S.L. Anti-proliferative synergy of lysophospholipid analogues and ketoconazole against Trypanosoma cruzi (Kinetoplastida: Trypanosomatidae): Cellular and ultrastructural analysis. J. Antimicrob. Chemother., 2005, 55, 780-784.
97. Bisser, S.; N'Siesi, F.X.; Lejon, V.; Preux, P.M.; Van Nieuwenhove, S.; Miaka Mia Bilenge, C.; Buscher, P. Equivalence trial of melarsoprol and nifurtimox monotherapy and combination therapy for the treatment of second-stage Trypanosoma brucei gambiense sleeping sickness. J. Infect. Dis., 2007, 195, 322-329.
98. http://www.dndi.org/press-releases (accessed on 15th June 2010)
99. Brajtburg, J.; Bolard, J. Carrier effects on biological activity of amphotericin B. Clin. Microbiol. Rev., 1996, 9, 512-531.
100. Veerareddy, P.R.; Vobalaboina, V. Lipid-based formulations of amphotericin B. Drugs Today, 2004, 40, 133-145.
101. Wingard, J.R.; Kubilis, P.; Lee, L.; Yee, G.; White, M.; Walshe, L.; Bowden, R.; Anaissie, E.; Hiemenz, J.; Lister, J. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin. Infect. Dis., 1999, 29, 1402-1407.
102. Eriksson, U.; Seifert, B.; Schaffner, A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: Randomised controlled trial. BMJ, 2001, 322, 579-582.
103. Llanos, A.; Cieza, J.; Bernardo, J.; Echevarria, J.; Biaggioni, I.; Sabra, R.; Branch, R.A. Effect of salt supplementation on amphotericin B nephrotoxicity. Kidney Int., 1991, 40, 302-308.
104. Torrado, J.J.; Espada, R.; Ballesteros, M.P.; Torrado-Santiago, S. Amphotericin B formulations and drug targeting. J. Pharm. Sci., 2008, 97, 2405-2425.
105. Kirby, C.; Clarke, J.; Gregariadis, G. Effect of the cholesterol content of small unilamellar liposomes on their stability in vivo and in vitro. Biochem. J., 1980, 186, 591-598.
106. Adler-Moore, J.; Proffitt, R.T. AmBisome: Liposomal formulation, structure, mechanism of action and pre-clinical experience. J. Antimicrob. Chemother., 2002, 49, 21-30.
107. Lemke, A.; Kiderlen, A.F.; Kayser, O. Amphotericin B. Appl. Microbiol. Biotechnol., 2005, 68, 151-162.
108. Bern, C.; Adler-Moore, J.; Berenguer, J.; Boelaert, M.; den Boer, M.; Davidson, R.N.; Figueras, C.; Gradoni, L.; Kafetzis, D.A.; Ritmeijer, K.; Rosenthal, E.; Royce, C.; Russo, R.; Sundar, S.; Alvar, J. Liposomal amphotericin B for the treatment of visceral leishmaniasis. Clin. Infect. Dis., 2006, 43, 917-924. (Pubitemid 44435523)
109. Alving, C.R. Liposomes as drug carriers in leishmaniasis and malaria. Parasitol. Today, 1986, 2, 101-107.
110. Hunter, C.A.; Dolan, T.F.; Coombs, G.H.; Baillie, A.J. Vesicular systems (niosomes and liposomes) for delivery of sodium stibogluconate in experimental murine visceral leishmaniasis. J. Pharm. Pharmacol., 1988, 40, 161-165.
111. Schettini, D. A.; Costa-Val, A.P.; Souza, L.F.; Demicheli, C.; Rocha, O.G.F.; Melo, M. N.; Michalick, M.S.M.; Frézard, F. Pharmacokinetic and parasitological evaluation of the bone marrow of dogs with visceral leishmaniasis submitted to multiple dose treatment with liposome-encapsulated meglumine antimoniate. Braz. J. Med. Biol. Res., 2005, 38, 1879-1883.
112. Schettini, D.A.; Ribeiro, R.R.; Demicheli, C.; Rocha, O.G.F.; Melo, M.N.; Michalick, M.S.M.; Frézard, F. Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size. Int. J. Pharm., 2006, 315, 140-147.
113. Schettini, D.A.; Costa-Val, A.P.; Souza, L.F.; Demicheli, C.; Rocha, O.G.F.; Melo, M.N.; Michalick, M.S.M.; Frézard, F. Distribution of liposome-encapsulated antimony in dogs. Braz. J. Med. Biol. Res., 2003, 36, 269-272.
114. Rakotomanga, M.; Loiseau, P.M.; Saint-Pierre-Chazalet, M. Hexadecylphosphocholine interaction with lipid monolayers. Biochim. Biophys. Acta, 2004, 1661, 212-218.
115. Pérez-Victoria, J.; Gamarro F.; Ouellette, M.; Castanys, S. Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance. J. Biol. Chem., 2003, 278, 49965-49971.
116. Barrats, G.; Saint-Pierre-Chazalet, M.; Loiseau, P.M. Cellular transport and lipid interactions of miltefosine. Curr. Drug. Metab., 2009, 10, 247-255
117. Papagiannaros, A.; Bories, C.; Demetzos, C.; Loiseau, P.M. Antileishmanial and trypanocidal activities of new miltefosine liposomal formulations. Biomed. Pharmacother., 2005, 59, 545-550.
118. El-On, J.; Jacobs, G.P.; Witztum, E.; Greenblatt, C.L. Development of topical treatment for cutaneous leishmaniasis caused by Leishmania major in experimental animals. Antimicrob. Agents Chemother., 1984, 26, 745-751.
119. Armijos, R.X.; Weigel, M.M.; Calvopina, M.; Mancheno, M.; Rodriguez, R. Comparison of the effectiveness of two topical paromomycin treatments versus meglumine antimoniate for New World cutaneous leishmaniasis. Acta Trop., 2004, 91, 153-160.
120. Iraji, F.; Sadeghinia, A. Efficacy of paromomycin ointment in the treatment of cutaneous leishmaniasis: Results of a double-blind, randomized trial in Isfahan, Iran. Ann. Trop. Med. Parasitol., 2005, 99, 3-9.
121. El-On, J.; Bazarsky, E.; Sneir, R. Leishmania major: In vitro and in vivo anti-leishmanial activity of paromomycin ointment (Leshcutan) combined with the immunomodulator Imiquimod. Exp. Parasitol., 2007, 116, 156-162.
122. Mussi, S.V.; Fernández, A.P.; Ferreira, L.A. Comparative study of the efficacy of formulations containing fluconazole or paromomycin for topical treatment of infections by Leishmania major and Leishmania amazonensis. Parasitol. Res., 2007, 100, 1221-1226.
123. Ben Salah, A.; Buffet, P.A.; Morizot, G.; Ben Massoud, N.; Zǎatour, A.; Ben Alaya, N.; Haj Hamida, N.B.; Ahmadi, Z.E.; Downs, M.T.; Smith, P.L.; Dellagi, K.; Grögl, M. WR279,396, a third generation aminoglycoside ointment for the treatment of Leishmania major cutaneous leishmaniasis: A phase 2, randomized, double blind, placebo controlled study. PLoS Negl. Trop. Dis., 2009, 3, e432.
124. Jaafari, M.R.; Bavarsad, N.; Bazzaz, B.S.; Samiei, A.; Soroush, D.; Ghorbani, S.; Heravi M.M.; Khamesipour, A. Effect of topical liposomes containing paromomycin sulfate in the course of Leishmania major infection in susceptible BALB/c mice. Antimicrob. Agents Chemother., 2009, 53, 2259-2265.
125. Kim, D.H.; Chung, H.J.; Bleys, J.; Ghohestani, R.F. Is paromomycin an effective and safe treatment against cutaneous leishmaniasis? A meta-analysis of 14 randomized controlled trials. PLoS Negl. Trop. Dis., 2009, 3, e381.
126. Morilla, M.J.; Montanari, J.A.; Prieto, M.J.; Lopez, M.O.; Petray, P.B.; Romero, E.L. Intravenous liposomal benznidazole as trypanocidal agent: Increasing drug delivery to liver is not enough. Int. J. Pharm., 2004, 278, 311-318.
127. Lamas, M.C.; Villaggi, L.; Nocito, I.; Bassani, G.; Leonardi, D.; Pascutti, F.; Serra, E.; Salomón, C.J. Development of parenteral formulations and evaluation of the biological activity of the trypanocide drug benznidazole. Int. J. Pharm., 2006, 307, 239-243.
128. Sánchez, G.; Cuellar, D.; Zulantay, I.; Fajardo, M.; González- Martin, G. Cytotoxicity and trypanocidal activity of nifurtimox encapsulated in ethylcyanoacrylate nanoparticles. Biol. Res., 2002, 35, 39-45.
129. Kedzierski, L.; Sakthianandeswaren, A.; Curtis, J.M.; Andrews, P.C.; Junk, P.C.; Kedzierska, K. Leishmaniasis: Current treatment and prospects for new drugs and vaccines. Curr. Med. Chem., 2009, 16, 599-614.
130. Duschak, V.G.; Couto, A.S. An insight on targets and patented drugs for chemotherapy of Chagas disease. Recent Pat. Antiinfect. Drug Discov., 2007, 2, 19-51.
131. Datta, A.K.; Datta, R.; Sen, B. Antiparasitic chemotherapy: Tinkering with the purine salvage pathway. Adv. Exp. Med. Biol., 2008, 625, 116-132.
132. Cohn, C.S.; Gottlieb, M. The acquisition of purines by trypanosomatids. Parasitol. Today, 1997, 13, 231-235.
133. Marr, J.J. Purine analogs as Chemotherapeutic-Agents in Leishmaniasis and American Trypanosomiasis. J. Lab. Clin. Med., 1991, 118, 111-119.
134. Maya, J.D.; Cassels, B.K.; Iturriaga- Vásquez, P.; Ferreira, J.; Faúndez, M.; Galanti, N.; Ferreira, A.; Morello, A. Mode of action of natural and synthetic drugs against Trypanosoma cruzi and their interaction with the mammalian host. Comp. Biochem. Physiol. A Mol. Integr. Physiol., 2007, 146, 601-620.
135. Momeni, A.Z.; Aminjavaheri, M. Successful treatment of nonhealing cases of cutaneous leishmaniasis, using a combination of meglumine antimoniate plus allopurinol. Eur. J. Dermatol., 2003, 13, 40-43.
136. Koutinas, A.F.; Saridomichelakis, M.N.; Mylonakis, M.E.; Leontides, L.; Polizopoulou, Z.; Billinis, C.; Argyriadis, D.; Diakou, N.; Papadopoulos, O. A randomised, blinded, placebo-controlled clinical trial with allopurinol in canine leishmaniosis.Vet. Parasitol., 2001, 98, 247-261.
137. Chowdhury, S.F.; Villamor, V.B.; Guerrero, R.H.; Leal, I.; Brun, R.; Croft, S.L.; Goodman, J.M.; Maes, L.; Ruiz-Perez, L.M.; González- Pacanowska, D.; Gilbert, I.H. Design, synthesis, and evaluation of inhibitors of trypanosomal and leishmanial dihydrofolate reductase J. Med. Chem., 1999, 42, 4300-4312. (Pubitemid 29504134)
138. Pez, D.; Leal, I.; Zuccotto, F.; Boussard, C.; Brun, R.; Croft, S.L; Yardley, V.; Ruiz, P.L.M.; González, P.D.; Gilbert, I.H. 2,4- Diaminopyrimidines as inhibitors of Leishmanial and Trypanosomal dihydrofolate reductase. Bioorg. Med. Chem., 2003, 11, 4693- 4711.
139. Sunduru, N.; Nishi, Palne, S.; Chauhan, P. M.S.; Gupta, S. Synthesis and antileishmanial activity of novel 2,4,6-trisubstituted pyrimidines and 1,3,5-triazines. Eur.J. Med. Chem., 2009, 44, 2473-2481.
140. D'Silva, C.; Daunes, S. The therapeutic potential of inhibitors of the trypanothione cycle. Expert Opin. Investig. Drugs, 2002, 11, 217-231.
141. Reguera, R.M.; Tekwani, B.L.; Balaña-Fouce R. Polyamine transport in parasites: A potential target for new antiparasitic drug development. Comp. Biochem. Physiol. C Toxicol. Pharmacol., 2005, 140, 151-164.
142. Fairlamb, A.H.; Cerami, A. Metabolism and functions of trypanothione in the Kinetoplastida. Annu. Rev. Microbiol., 1992, 46, 695-729.
143. Heby, O.; Persson, L.; Rentala, M. Targeting the polyamine biosynthetic enzymes: A promising approach to therapy of African sleeping sickness, Chagas' disease, and leishmaniasis. Amino Acids, 2007, 33, 359-366.
144. Gonzalez, N.S.; Huber, A.; Algranati, I.D. Spermidine is essential for normal proliferation of trypanosomatid protozoa. FEBS Lett., 2001, 508, 323-326.
145. Singh, S.; Mukherjee, A.; Khomutov, A.R.; Persson, L.; Heby, O.; Chatterjee, M.; Madhubala, R. Antileishmanial effect of 3- aminooxy-1- aminopropane is due to polyamine depletion. Antimicrob. Agents Chemother., 2007, 51, 528-534.
146. Bacchi, C.J.; Brun, R.; Croft, S.L.; Alicea, K.; Bühler, Y. In vivo trypanocidal activities of new S-adenosylmethionine decarboxylase inhibitors. Antimicrob. Agents Chemother., 1996, 40, 1448-1453. (Pubitemid 26170000)
147. Barker, Jr. R.H.; Liu, H.; Hirth, B.; Celatka, C.A.; Fitzpatrick, R.; Xiang, Y.; Willert, E.K.; Phillips, M.A.; Kaiser, M.; Bacchi, C.J. Rodriguez, A.; Yarlett, N.; Klinger, J.D.; Sybertz, E. Novel Sadenosylmethionine decarboxylase inhibitors for the treatment of human African trypanosomiasis. Antimicrob. Agents Chemother., 2009, 53, 2052-2058.
148. Roberts, S.C.; Jiang, Y.; Gasteier, J.; Frydman, B.; Marton, L.J.; Heby, O.; Ullman, B. Leishmania donovani polyamine biosynthetic enzyme overproducers as tools to investigate the mode of action of cytotoxic polyamine analogs. Antimicrob. Agents Chemother., 2007, 51, 438-445.
149. Michels, P.A.M.; Hannaert, V.; Bringaud, F. Metabolic aspects of glycosomes in trypanosomatidae-new data and views. Parasitol. Today, 2000, 16, 482-489.
150. Nowicki, M.W.; Tulloch, L.B.; Worrall, L.; McNae, I.W.; Hannaert, V.; Michels, P.A.; Fothergill-Gilmore, L.A.; Walkinshaw, M.D.; Turner, N.J. Design, synthesis and trypanocidal activity of lead compounds based on inhibitors of parasite glycolysis. Bioorg. Med. Chem., 2008, 16, 5050-5061.
151. Rodenko, B.; Van der Burg, A.M.; Wanner, M.J.; Kaiser, M.; Brun, R.; Gould, M.; de Koning, H. P.; Koomen, G.J. 2,N6-disubstituted adenosine analogs with antitrypanosomal and antimalarial activities Antimicrob. Agents Chemother., 2007, 51, 3796-3802.
152. Leitao, A.; Andricopulo, A.D.; Oliva, G.; Pupo, M.T.; de Marchi, A.A.; Vieira, P.C.; da Silva, M.F.; Ferreira, V.F.; de Souza, M.C.B.V.; Sá, Marcus M.; Moraes, V.R.S.; Montanaria, C.A. Structure-activity relationships of novel inhibitors of glyceraldehyde-3-phosphate dehydrogenase. Bioorg. Med. Chem. Lett., 2004, 14, 2199-2204.
153. Dardonville, C.; Rinaldi, E.; Barrett, M.P.; Brun, R.; Gilbert, I.H.; Hanau, S. Selective inhibition of Trypanosoma brucei 6- phosphogluconate dehydrogenase by high-energy intermediate and transition-state analogues. J. Med. Chem., 2004, 47, 3427-3437.
154. Roberts, C.W.; McLeod, R.; Rice, D.W.; Ginger, M.; Chance, M.L.; Goad, L.J. Fatty acid and sterol metabolism: Potential antimicrobial targets in apicomplexan and trypanosomatid parasitic protozoa. Mol. Biochem. Parasitol., 2003, 126, 129-142.
155. Urbina, J.A.; Concepcion, J.L.; Caldera, A.; Payares, G.; Sanoja, C.; Otomo, T.; Hiyoshi, H. In vitro and in vivo activities of E5700 and ER-119884, two novel orally active squalene synthase inhibitors, against Trypanosoma cruzi. Antimicrob. Agents Chemother., 2004, 48, 2379-2387.
156. Zakai, H.A.; Zimmo, S.K. Effects of itraconazole and terbinafine on Leishmania major lesions in BALB/c mice. Ann. Trop. Med. Parasitol., 2000, 94, 787-791.
157. Momeni, A.Z.; Aminjavaheri, M.; Omidghaemi, M.R. Treatment of cutaneous leishmaniasis with ketoconazole cream. J. Dermatolog. Treat., 2003, 14, 26-29;
158. Consigli, J.; Danielo, C.; Gallerano, V.; Papa, M.; Guidi, A. Cutaneous leishmaniasis: Successful treatment with itraconazole. Int. J. Dermatol., 2006, 45, 46-49;
159. Alrajhi, A.A.; Ibrahim, E.A.; De Vol, E.B.; Khairat, M.; Faris, R.M.; Maguire, J.H. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. New Engl. J. Med., 2002, 346, 891-895; Sundar, S.; Singh, V.P.; Agrawal, N.K.; Gibbs, D.L.; Murray, H.W. Treatment of kala-azar with oral fluconazole. Lancet, 1996, 348, 614.
160. Pagniez, F.; Abdala-Valencia, H.; Marchand, P.; Leborgne M.; Le Baut, G.; Robert-Piessard, S.; Le Pape, P. Antileishmanial activities and mechanisms of
161. Urbina, J.A.; Payares G.; Sanoja, C.; Lira, R.; Romanha A.J. In vitro and in vivo activities of ravuconazole on Trypanosoma cruzi, the causative agent of Chagas disease. Int. J. Antimicrob. Agents, 2003, 21, 27-38.
162. Urbina J.A.; Payares, G.; Santoja, C.; Molina, J.; Lira, R.; Brener, Z, Romanha A.J. Parasitological cure of acute and chronic experimental Chagas disease using the long-acting experimental triazole TAK-187. Activity against drug-resistant Trypanosoma cruzi strains. Int. J. Antimicrob. Agents, 2003, 21, 39-48.
163. Martin, M.B.; Grimley, J.S.; Lewis, J.C.; Heath, H.T.; Bailey, B.N.; Kendrick, H.; Yardley, V.; Caldera, A.; Lira, R.; Urbina, J. A.; Moreno, S. N.; Docampo, R. Croft, S.; Oldfield, E. Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: A potential route to chemotherapy. J. Med. Chem., 2001, 44, 909-916.
164. Szajnman, S.H.; Ravaschino, E.L.; Docampo, R.; Rodriguez, J. B. Synthesis and biological evaluation of 1-amino-1,1-bisphosphonates derived from fatty acids against Trypanosoma cruzi targeting farnesyl pyrophosphate synthase. Bioorg. Med. Chem. Lett., 2005, 15, 4685-4690.
165. Kraus, J.M.; Verlinde, C.L.M.J.; Karimi, M.; Lepesheva, G.I.; Gelb, M.H.; Buckner, F.S. Rational modification of a candidate cancer drug for use against Chagas disease. J. Med. Chem., 2009, 52, 1639-1647.
166. Das, A.; Dasgupta, A.; Sengupta ,T.; Majumder, H.K. Topoisomerases of kinetoplastid parasites as potential chemotherapeutic targets. Trends Parasitol., 2004, 20, 381-387.
167. Bodley, A.L.; Shapiro, T.A. Molecular and cytotoxic effects of camptothecin, a topoisomerase I inhibitor, on trypanosomes and Leishmania. Proc. Natl. Acad. Sci. USA, 1995, 92, 3726-3730.
168. Fuertes, M.A.; Nguewa, P.A.; Castilla, J.; Alonso, C.; Pérez, J.M. Anticancer compounds as leishmanicidal drugs: Challenges in chemotherapy and future perspectives. Curr. Med. Chem., 2008, 15, 433-439.
169. Huang, T.L.; Bacchi, C.J.; Kode, N.R.; Zhang, Q.; Wang, G.; Yartlet, N.; Rattendi, D.; Londono, I.; Mazumder, L.; Vanden- Eynde, J.J.; Mayence, A.; Donkor, I.O. Trypanocidal activity of piperazine-linked bisbenzamidines and bisbenzamidoxime, an orally active prodrug. Int. J. Antimicrob. Agents, 2007, 30, 555- 561;
170. Mayence, A.; Pietka, A.; Collins, M.S.; Cushion, M.T.; Tekwani, B.L.; Huang, T.L. Vanden Eyndea, J.J. Novel bisbenzimidazoles with antileishmanial effectiveness. Bioorg. Med. Chem. Lett., 2008, 18, 2658-2661;
171. Hu, L.; Arafa, R.K.; Ismail, M.A.: Wenzler, T.; Brun, R.; Munde, M.; Wilson, W.D.; Nzimiro, S.; Samyesudhas, S.; Werbovetz, K.A.; Boykin, D.W. Azaterphenyl diamidines as antileishmanial agents. Bioorg. Med. Chem. Lett., 2008, 18, 247-251;
172. Werbovetz, K. Diamidines as antitrypanosomal, antileishmanial and antimalarial agents. Curr. Opin. Investig. Drugs, 2006, 7,147-157.
173. Silva, C.F.; Meuser, M.B.; De Souza, E.M.; Meirelles, M.N.L.; Stephens, C.E.; Som, P.; Boykin, D.W.; Soeiro, M.N.C. Cellular effects of reversed amidines on Trypanosoma cruzi. Antimicrob. Agents Chemother., 2007, 51, 3803-3809.
174. Ismail, M.A.; Arafa, R.K.; Wenzler, T.; Brun, R.; Tanious, F.A.; Wilson, W.D.; Boykin, D.W. Synthesis and antiprotozoal activity of novel bis-benzamidino imidazo[1,2-α]pyridines and 5,6,7,8- tetrahydro-imidazo[1,2-α] pyridines. Bioorg. Med. Chem., 2008, 16, 683-691.
175. Rodríguez, F.; Rozas, I.; Kaiser, M.; Brun, R.; Nguyen, B.; Wilson, W.D.; García, R.N.; Dardonville, C. New bis(2-aminoimidazoline) and bisguanidine DNA minor groove binders with potent in vivo antitrypanosomal and antiplasmodial activity. J. Med. Chem., 2008, 51, 909-923.
176. George, T.G.; Johnsamuel, J.; Delfín, D.A.; Yakovich, A.J.; Mukherjee, M.S.; Phelps, M.A.; Dalton, J.T.; Sackett, D.L.; Kaiser, M.; Brun, R.; Werbovetz, K.A. Antikinetoplastid antimitotic activity and metabolic stability of dinitroaniline sulfonamides and benzamides Bioorg. Med. Chem., 2006, 14, 5699-5710;
177. George, T.G.; Endeshaw, M.M.; Morgan, R. E.; Mahasenan, K.V.; Delfín, D.A.; Mukherjee, M.S.; Yakovich, A.J; Fotie, J.; Li, C.; Werbovetz, K.A. Synthesis, biological evaluation, and molecular modeling of 3,5- substituted-N1-phenyl-N4,N4-di-n-butylsulfanilamides as antikinetoplastid antimicrotubule agents. Bioorg. Med. Chem., 2007, 15, 6071-6079.
178. Quintin, J.; Desrivot, J.; Thoret, S.; Le Menez, P.; Cresteil, T.; Lewin, G. Synthesis and biological evaluation of a series of tangeretin- derived chalcones. Bioorg. Med. Chem. Lett., 2009, 19, 167-169.
179. Andrighetti-Frohner, C.R.; de Oliveira, K.N.; Gaspar-Silva, D.; Pacheco, L.K.; Joussef, A.C.; Steindel, M.; Simoes, C.M.O.; de Souza, A.M.T.; Magalhaes, U.O.; Afonso, I.F.; Rodrigues, C.R.; Nunes, R.J.; Castro, H.C. Synthesis, biological evaluation and SAR of sulfonamide 4-methoxychalcone derivatives with potential antileishmanial activity. Eur. J. Med. Chem., 2009, 44, 755-763.
180. Sajid, M.; McKerrow, J.R. Cysteine proteases of parasitic organisms. Mol. Biochem. Parasitol., 2002, 120, 1-21.
181. Caffrey, C.R.; Scory, S.; Steverding, D. Cysteine proteinases of trypanosome parasites: Novel targets for chemotherapy. Curr. Drug Targets, 2000, 1, 155-162; Du, X.; Guo, C.; Hansell, E.; Doyle, P.S.; Caffrey, C.R.; Holler, T.P.; McKerrow, J.H.; Cohen, F.E. Synthesis and structure-activity relationship study of potent trypanocidal thio semicarbazone inhibitors of the trypanosomal cysteine protease cruzain. J. Med. Chem., 2002, 45, 2695-2707.
182. Mukherjee, S.; Ukil, A.; Das, P.K. Immunomodulatory peptide from cystatin, a natural cysteine protease inhibitor, against leishmaniasis as a model macrophage disease. Antimicrob. Agents Chemother., 2007, 51, 1700-1707.
183. Austin, S.E.; Khan, M.O.; Douglas, K.T. Rational drug design using trypanothione reductase as a target for anti-trypanosomal and anti-leishmanial drug leads. Drug Des. Discov., 1999, 16, 5-23.
184. Dardonville, C.; Rinaldi, E.; Hanau, S.; Barrett, M.P.; Brun, R.; Gilbert, I.H. Synthesis and biological evaluation of substrate-based inhibitors of 6-phosphogluconate dehydrogenase as potential drugs against African trypanosomiasis. Bioorg. Med. Chem., 2003, 11, 3205-3214.
185. Bressi, J.C.; Verlinde, C.L.; Aronov, A.M.; Shaw, M.L.; Shin, S.S.; Nguyen, L.N.; Suresh, S.; Buckner, F.S.; Van Voorhis, W.C.; Kuntz, I.D.; Hol, W.G.; Gelb, M.H. Adenosine analogues as selective inhibitors of glyceraldehyde-3-phosphate dehydrogenase of Trypanosomatidae via structure-based drug design. J. Med. Chem., 2001, 44, 2080-2093.
186. Maria A.F.; Vera-DiVaio, A.; Freitas, C.C.; Castro, H.C.; Albuquerque, S.; Cabral, L.M.; Rodrigues, C.R.; Albuquerque, M.G.; Martins, R.C.A.; Henriques, M.G.M.O.; Dias, L.R.S. Synthesis, antichagasic in vitro evaluation, cytotoxicity assays, molecular modeling and SAR/QSAR studies of a 2-phenyl-3-(1-phenyl-1Hpyrazol- 4-yl)-acrylic acid benzylidene-carbohydrazide series. Bioorg. Med. Chem., 2009, 17, 295-302.
187. Fávero, P.; Salomão, J.; Viana de Almeida, L.; Mesquita Pasqualoto, K.F.; Costa Tavares, L. Molecular modeling studies and in vitro bioactivity evaluation of a set of novel 5-nitroheterocyclic derivatives as anti-T. cruzi agents. Bioorg. Med. Chem., 2009, 17, 2673-2679.
188. Bhattacharjee, A.K. Virtual screening of compound libraries using in silico three dimensional pharmacophores to aid the discovery and design of antimalarial and antileishmanial agents. Frontiers Drug Design Discovery, 2007, 3, 257-292.
189. George, S.St.; Bishop, J.V.; Titus, R.G.; Selitrennikoff, C.P. Novel compounds active against Leishmania major. Antimicrob. Agents Chemother., 2006, 50, 474-479.
190. Mackey, Z.B.; Baca, A.M.; Mallari, J.P.; Apsel, B.; Shelat, A.; Hansell, E.J. Chiang, P.K.; Wolff, B.; Guy, K.R.; Williams, J.; McKerrow, J.H. Discovery of trypanocidal compounds by whole cell HTS of Trypanosoma brucei. Chem. Biol. Drug Des., 2006, 67, 355-363.
191. Montero-Torres, A.; Celeste Vega, A.; Marrero-Ponce, Y.; Rolón, M.; Gómez-Barrio, A.; Escario, J.A.; Arán, V.J.; Martínez- Fernández, A.R.; Meneses-Marcel, A. A novel non-stochastic quadratic fingerprints-based approach for the 'in silico' discovery of new antitrypanosomal compounds. Bioorg. Med. Chem., 2005, 13, 6264-6275.
192. Roldos, V.; Nakayama, H.; Rolón, M.; Montero- Torres, A.; Trucco, F.; Torres, S.; Vega, C.; Marrero-Ponce, Y., Heguaburu, V.; Yaluff, G.; Gómez-Barrio, A.; Sanabria, L.; Ferreira, M.E.; Rojas de Arias, A.; Pandolfi, E. Activity of a hydroxybibenzyl bryophyte constituent against Leishmania spp. and Trypanosoma cruzi: In silico, in vitro and in vivo activity studies. Eur. J. Med. Chem., 2008, 43, 1797-1807.
193. Cruz, A.K.; de Toledo J.S.; Falade, M.; Terrão, M.C.; Kamchonwongpaisan, S.; Kyle, D.E.; Uthaipibull, C. Current treatment and drug discovery against Leishmania spp. and Plasmodium spp.: A review. Curr. Drug Targets, 2009, 10, 178-192.